1Wahl RL.Principle and practice of positron emission tomography [M].Philadephia:Lippincott Williams & Wilkins,2003.157-251.
2Jager PL,Vaalburg W,Pruim J,et al.Radiolabeled amino acids:Basic aspects and clinical application in oncology [J].J Nucl Med,2001,42(3):432-445.
3Kelloff GJ,Hoffman JM,Johnson B,et al.Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development [J].Clin Cancer Res,2005,11(8):2785-2808.
4Matthies A,Hickeson M,Cuchiara A,et al.Dual time point 18F-FDG PET for the evaluation of pulmonary nodules [J].J Nucl Med,2002,43(7):871-875.
9Collingridge DR,Glaser M,Osman S,et al.In vitro selectivity,in vivo biodistribution and tumor uptake of AnnexinⅤ radiolabelled with a positron emitting radipisotope [J].Br J Cancer,2003,89(7):1327-1333.
10Ito M,Tomiyosh K,Takahashi N,et al.Development of a new ligand,11C-AnnexinⅤ,for PET imaging of apoptosis [J].J Nucl Med,2002,43(5 Suppl):362.
二级参考文献44
1Boerman O C, Oyen W J G, Corstens F H M. Between the scylla and charybdis of peptide radionuclide therapy:hitting the tumor and saving the kidney[J]. Eur J Nucl Med, 2001, 28:1447-1449.
2Forssell-Aronsson E, Bernhardt P, Nilsson O, et al. Biodistribution data from 100 patients iv. injected with 111In-DTPA-D-pheloctreotide [J]. Acta Oncol, 2004, 43(5): 436-442.
3Bushnell D, Menda Y, O' Dorisio T, et al. Effect of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-octreotide (SMT487[Octreo TherTM])treatment[J]. Cancer Biother Radiopharm,2004, 19(1): 35-41.
4Pauwels S, Barone R, Walrand S, et al. Practical dosimetry of peptide receptor radionuclide therapy with 90Y-labeled somatostatin analogs[J]. J Nucl Med, 2005, 46(1 suppl): 92S-98S.
5Moll S, Nickeleit V, Mueller-Brand J, et al. A new cause of renal thrombotic microangiopathy: Yttrium-90-DOTATOC internal radiotherapy[J]. Am J kidney Dis, 2001,37(4): 847-851.
6Bodei L, Cremonesi M, Zoboli S, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion, a phase Ⅰ study[J]. Eur J Nucl Med Mol Imaging, 2003,30(2): 207-216.
7Rolleman E J, Valkema R, de Jong M, et al. Safe and effective inhibition of renal uptake of radiolabelled octreotidc by a combination of lysine and arginine[J]. Eur J Nucl Med Mol Imaging, 2003, 30(1):9-15.
8Barone R, Pauwels S, De Camps J, et al. Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogs[J]. Nephrol Dial Transplant, 2004, 19(9): 2275-2281.
9Barone R, Borson-Chazot F, Valkema R, et al. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevence of kidney volume and dose rate in finding a dose-effect relationship [J]. J Nucl Med, 2005, 46(lsuppl): 99s-106s.
10Gabriel M, Froehlich F, Decristoforo C, et al. EDDA/HYNIC-TOC and 18F-FDG in thyroid cancer patients with negative 131I whole body scan[J]. Eur J Nucl Med Mol Imaging, 2004, 31(3): 330-341.
